Moderna, Inc. (MRNA) saw its stock price soar 5.33% during intraday trading on Wednesday, marking a significant upward movement for the biopharmaceutical company.

The rally is attributed to continued positive momentum from several recent developments. The company's Science Day event, held on June 25, served as a key catalyst, where Moderna disclosed its in-vivo CAR-T project mRNA-6007 for the first time. This project targets B-cell mediated autoimmune diseases and is planned to enter clinical trials next year. The event also showcased an extensive pipeline including tumor vaccines, cancer prevention vaccines, and an AI-powered R&D platform, reinforcing the market's view of Moderna's transition into a platform biopharmaceutical enterprise. Following the event, analysts at Piper Sandler and Jefferies raised their price targets on the stock.

Further supporting the positive sentiment is the recent unanimous recommendation (9-0) by an FDA advisory committee for the approval of Moderna's seasonal influenza vaccine, mRNA-1010, for adults aged 50 and older. A final FDA decision is expected by early August. In preparation for potential new product launches, the company has also appointed a new Chief Commercial Officer and reorganized its operational structure.